Evidence map›Paper›PMID 40986147›Full record

ArticleIn vitro cellular & developmental biology. Animal2025

The active ingredient of Ginkgo biloba extract (quercetin) improved H

Jingchi Sun, Zhousong Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jingchi SunDepartment of Medical Administration, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
Zhousong ZhengDepartment of Geriatrics, Zhuzhou Central Hospital, Zhuzhou, Hunan, China. zhengzsong0903@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activated microglia are considered to be closely related to brain senescence and the pathogenesis of neurodegenerative diseases. Ginkgo biloba extract (GBE) is widely used to treat cognitive impairment and Alzheimer's disease (AD). This study aims to investigate the active ingredients of GBE and the underlying molecular mechanisms. The active ingredients of GBE in AD treatment were first analyzed by network pharmacology, culminating in the identification of the key ingredient, quercetin, and its targeted protein, NQO1. GO function enriched the oxidative stress pathway, while KEGG enriched the PI3K/Akt/mTOR pathway. Quercetin binding to NQO1 was verified by molecular docking and DARTS analysis. Cytotoxicity assay revealed no significant toxicity of GBE (0-1 mg/mL) and quercetin (0-0.4 μM) over 48 h. Subsequently, we constructed the microglial injury model by H

Indexed as

MicrogliaNAD(P)H Dehydrogenase (Quinone)Plant ExtractsQuercetinSignal TransductionAnimalsCell LineCellular SenescenceGinkgo bilobaGinkgo ExtractHumansHydrogen PeroxideMiceMolecular Docking SimulationOxidative StressPhosphatidylinositol 3-KinasesGinkgo biloba extractGinkgo ExtractHydrogen PeroxideNAD(P)H Dehydrogenase (Quinone)Nqo1 protein, mousePhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktQuercetinTOR Serine-Threonine KinasesGinkgo biloba extractMicroglia injuryNQO1Quercetin

Identifiers

PMID40986147

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.